版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Chest2008;133(suppl)Chest2008;133(suppl)PrimarypreventionofVTEPrimarypreventionofVTERATIONALEFORTHROMBOPROPHYLAXISINHOSPITALIZEDPATIENTS-1HighprevalenceofVTEAlmostallhospitalizedpatientshaveoneormoreriskfactorsforVTETheincidenceofDVTisashighas80%insomehospitalizedpatientgroupsHospital-acquiredDVTandPEareusuallyclinicallysilentItisdifficulttopredictwhichat-riskpatientswilldevelopsymptomaticthromboemboliccomplicationsScreeningat-riskpatientsusingphysicalexaminationornoninvasivetestingisneithercost-effectivenoreffectiveRATIONALEFORTHROMBOPROPHYLAXRATIONALEFORTHROMBOPROPHYLAXISINHOSPITALIZEDPATIENTS-2AdverseconsequencesofunpreventedVTESymptomaticDVTandPE:postopVTEsecondmostcommonmedicalcomplicationFatalPE:PEisthemostcommoncauseofpreventablehospitaldeathCostsofinvestigatingsymptomaticpatientsRisksandcostsoftreatingunpreventedVTEIncreasedfutureriskofrecurrentVTEChronicpostthromboticsyndromeRATIONALEFORTHROMBOPROPHYLAXRATIONALEFORTHROMBOPROPHYLAXISINHOSPITALIZEDPATIENTS-3EfficacyofthromboprophylaxisThromboprophylaxisishighlyefficaciousatpreventingDVTandproximalDVTThromboprophylaxisishighlyeffectiveatpreventingsymptomaticVTEandfatalPEThepreventionofDVTalsopreventsPECost-effectivenessofthromboprophylaxishasrepeatedlybeendemonstratedRATIONALEFORTHROMBOPROPHYLAXRISKFACTORSFORVTESurgeryTrauma(majortraumaorlower-extremityinjury)Immobility,lower-extremityparesisObesityIncreasingageCancer(activeoroccult)Cancertherapy(hormonal,chemotherapy,angiogenesisinhibitors,radiotherapy)Venouscompression(tumor,hematoma,arterialabnormality)PreviousVTEPregnancyandthepostpartumperiodEstrogen-containingoralcontraceptivesorhormonereplacementtherapySelectiveestrogenreceptormodulatorsErythropoiesis-stimulatingagentsAcutemedicalillnessInflammatoryboweldiseaseNephroticsyndromeMyeloproliferativedisordersParoxysmalnocturnalhemoglobinuriaCentralvenouscatheterizationInheritedoracquiredthrombophiliaRISKFACTORSFORVTESurgeryTHROMBOPHILIAInheritedAntithrombindeficiencyProteinCdeficiencyProteinSdeficiencyFactorVLeiden(heterozygousorhomozygous)ProthrombinG20210AgenemutationAcquiredAntiphospholipidsyndromeHighestrisk:Antithrombindeficiency,homozygousFactorVLeidenorcompoundheterozygotes,antiphospholipidsyndromeTHROMBOPHILIAInheritedMostthromboticeventsoccurafterhospitaldischargeRISKOFDVTINHOSPITALIZEDPATIENTSNOTRECEIVINGPROPHYLAXISMostthromboticeventsoccuraREGIMENSTOPREVENTVTELowdoseunfractionatedheparin(5000Uq8-12h)Lowmolecularweightheparin(dalteparin2500Uq12-24h;enoxaparin30mgq12hor40mgdaily)Fondaparinux(2.5mgsqoncedaily)Warfarin:AdjusttotargetINR2-3Mechanicalmethods:gradedcompressionstockings,intermittentpneumaticcompression,venousfootpumpAspirinappearstobelesseffective,notrecommendedassolemethodofprophylaxisREGIMENSTOPREVENTVTELowdosRelativeefficacyofvariousthromboprophylacticregimensfollowingTHR:meta-analysisTreatmentAllDVT(%)ProxDVT(%)Bleeding(%)None47230.3Aspirin36160.4UFH24142.6LMWH1761.8Stockings18130Warfarin2451.3JAMA1994;271:22RelativeefficacyofvarioustTHROMBOPROPHYLACTICDRUGSAgentAdvantagesDisadvantagesHeparinCostHITriskShorterhalf-lifeLMWHLowerriskofHITOncedailydosingoptionCostIncreasedbloodlevelsinrenalfailureWarfarinOraldrugCostNoHITriskVariabledose-responseDelayedonsetofeffectNeedformonitoringFondaparinuxEfficacy?(vsLMWH)OncedailydosingMinimalHITriskCostIncreasedbleeding?HighbloodlevelsinrenalfailureTHROMBOPROPHYLACTICDRUGSAgentUnfractionatedhepariningeneralsurgeryMeta-analysisof46RCTscomparingUFHandplaceboornotreatmentUFHreducedDVTratefrom22%to9%ReducedsymptomaticPEratefrom2.0%to1.3%ReducedfatalPEratefrom0.8%to0.3%Reducedallcausemortalityfrom4.2%to3.2%(onelessdeathper97patientstreated)Increasedbleedingratefrom3.8%to5.9%(mostbleedsminor)NEnglJMed1988;318:1162UnfractionatedhepariningeneLMWHinsurgeryGeneralsurgery:LMWHreducesriskofasymptomaticDVTandsymptomaticVTEbyover70%vsnotreatmentRoughlyequivalenttoUFHintermsofefficacyandsafetyLMWHappearssuperiortoUFHinhigh-riskorthopedicsurgeryNostudyhasshownclearsuperiorityofoneformofLMWHoveranother2008ACCPguidelinesLMWHinsurgeryGeneralsurgeryFONDAPARINUXSelectiveXainhibitor(doesnotinhibitthrombin)Longhalf-life(oncedailydosing),noantidoteEquivalentorslightlysuperiortoLMWHforpreventionofpostoperativeVTESlightlyhigherbleedingriskFONDAPARINUXSelectiveXainhibFONDAPARINUXVSENOXAPARININORTHOPEDICSURGERY
PooledresultsfromfourpivotaltrialsOutcomeFondaparinuxEnoxaparinOddsRatio(95%CI)AllVTE6.8%13.7%0.45(0.37-0.54)ProximalDVT1.3%2.9%0.43(0.27-0.64)MajorBleed2.7%1.7%1.54(1.11-2.16)Lancet2002;359:1710FONDAPARINUXVSENOXAPARININMechanicalthromboprophylaxisAdvantagesNobleedingriskDemonstratedefficacy(butlimitedevidence)EnhanceefficacyofanticoagulantprophylaxisReducelegswellingDisadvantagesLesswell-studiedthananticoagulantsLesswell-standardizedNotalldeviceshavebeenevaluatedintrialsLesseffectiveinhigh-riskgroupsLesseffectiveinpreventingproximalDVTNotshowntopreventPEordeathComplianceissuesMechanicalthromboprophylaxisARisk-adaptedVTEprophylaxis-1LevelofRiskApproximateVTEriskwithoutprophylaxisSuggestedthromboprophylaxisoptionsLowRisk:MinorsurgeryinmobilepatientsFullymobilemedicalpatients<10%NospecificprophylaxisEarlyand“aggressive”ambulationRisk-adaptedVTEprophylaxis-Risk-adaptedVTEprophylaxis-2LDUH,low-doseunfractionatedheparin;LMWH,lowmolecularweightheparin*Mechanicalprophylaxis=graduatedcompressionstockings,intermittentpneumaticcompressionorvenousfootpumpLevelofRiskApproximateVTEriskwithoutprophylaxisSuggestedthromboprophylaxisoptionsModerateRisk:Mostgeneral,openGYNorurologicsurgeryMedicalpatientsatbedrestorsick10-40%LMWHLDUHbidortidFondaparinuxIfbleedingriskhigh:mechanicalprophylaxis*Risk-adaptedVTEprophylaxis-Risk-adaptedVTEprophylaxis-3LMWH,lowmolecularweightheparin*Mechanicalprophylaxis=graduatedcompressionstockings,intermittentpneumaticcompressionorvenousfootpumpLevelofRiskApproximateVTEriskwithoutprophylaxisSuggestedthromboprophylaxisoptionsHighRisk:Hiporkneearthroplasty,hipfracturesurgery,majortrauma,spinalcordinjury40-80%LMWHFondaparinux,Warfarin(INR2-3)Ifbleedingriskhigh:mechanicalprophylaxis*Risk-adaptedVTEprophylaxis-KNEEARTHROSCOPYSymptomaticDVTrate<1%withoutprophylaxisAsymptomaticDVTmorecommon(upto18%)Therapeutic(vsdiagnostic)procedure,longertourniquettimeassociatedwithhigherDVTratesRoutinethromboprophylaxisnotrecommendedLMWHrecommendedforpatientswithadditionalriskfactors,orafterprolonged/complicatedprocedures2008ACCPguidelinesKNEEARTHROSCOPYSymptomaticDVSPINALOREPIDURALANESTHESIAReportsofperispinalhematomasinpatientsreceivingLMWHExactprevalenceunknownFewreportswithlowdoseUFHaswellRiskfactors:coagulopathyanatomicspineabnormalitiesdifficultinsertion/repeatedattemptshigherdosesofanticoagulantcontinuousepiduralcatheterolderageSPINALOREPIDURALANESTHESIARSPINALOREPIDURALANESTHESIA
RECOMMENDATIONSAvoidinpatientswithknowncoagulopathyD/Cclopidogrel(Plavix)atleast5daysbeforeASAsafer?Needleinsertionandepiduralcatheterremovalatleast8hoursafterlastdoseofLMWHiftwicedaily,or18hafterlastdoseifoncedailyWaitatleast2hbeforerestartingLMWH,longerifCSFbloodyDonotusecontinuousepiduralanesthesiaformorethan2daysifpttakingwarfarin;INRshouldbe<1.5whencatheterremovedFondaparinuxnotrecommended(longhalf-life,littledata)Monitorforsignsofcordcompression2008ACCPguidelinesSPINALOREPIDURALANESTHESIA
TIMINGOFTHROMBOPROPHYLAXISStartingLMWHjustbeforeorwithin6hoursafterhigh-risksurgerymosteffective“appearstobelittleornoadvantage”tostartingpre-opDelayuntil12-24hourspostopforpatientswithhighbleedingriskStartfondaparinux6-8hpostop,ornextday2008ACCPguidelinesTIMINGOFTHROMBOPROPHYLAXISStDURATIONOFTHROMBOPROPHYLAXISMostsymptomaticVTEeventsoccurafterdischargeRiskofVTEincreasedfor2-3monthsafterhipreplacementExtendedprophylaxis(upto35days)reducesVTErisk,butbleedingratehigherPatientsshouldreceiveprophylaxisforatleast10daysafterhigh-riskorthopedicsurgery,andfor25-30daysifthereareadditionalriskfactorsforVTE(LMWH,warfarinorfondaparinux)2008ACCPguidelinesDURATIONOFTHROMBOPROPHYLAXISThromboprophylaxisinpregnancyThromboprophylaxisinpregnancLOWMOLECULARWEIGHTHEPARINISSAFEANDEFFECTIVEINPREGNANCYDatafrom64studies,2777pregnanciesMainindicationwasthromboprophylaxisNomaternaldeaths0.86%incidenceofthrombosis1.98%incidenceofsignificantbleedingNocasesofHIT0.04%incidenceofosteoporoticfracture94.7%livebirthrateBlood2005;106:401LOWMOLECULARWEIGHTHEPARINIVTEPROPHYLAXISINPREGNANCY
RECOMMENDATIONS-1Forwomenwithhistoryof:VTEassociatedwithestrogenuseorpregnancyVTEandthrombophiliaIdiopathicVTE,nolong-termanticoagulationTreatwithprophylacticorintermediate-dose*LMWH(preferred)orUFH,orcloseclinicalsurveillance,plusanticoagulant(egwarfarin)forsixweekspostpartum*Dalteparin5000Uq12horenoxaparin40mgq12h2008ACCPguidelinesVTEPROPHYLAXISINPREGNANCY
RVTEPROPHYLAXISINPREGNANCY
RECOMMENDATIONS-2Forwomenwith:HxofVTEand“highrisk”thrombophiliaRecurrentVTEHxofVTEonlong-termanticoagulantRxTreatwithprophylactic,intermediate-,oradjusted-doseLMWHorUFH,plusanticoagulantforsixweekspostpartum2008ACCPguidelinesVTEPROPHYLAXISINPREGNANCY
RVTEPROPHYLAXISINPREGNANCY
RECOMMENDATIONS-3Patientpreferencemustbetakenintoaccount(avoiding“medicalization”ofpregnancyvsavoidingfetalrisk)LMWHispreferredtoUFHduringpregnancyAllpregnantwomenwithahistoryofVTEshouldusegraduatedelasticcompressionstockingsduringandforsixweeksafterpregnancyThereisnocontraindicationtousingLMWH,UFHorwarfarinwhilenursingFondaparinuxshouldbeavoidedduringpregnancyunlessthereisahistoryofHIT2008ACCPguidelinesVTEPROPHYLAXISINPREGNANCY
RINFERIORVENACAVAFILTERSDefiniteindicationsAnticoagulationfailureafterproximalDVTorPEAnticoagulationcontraindicated,recentproximalDVTorPELife-threateninghemorrhageonanticoagulationforrecentVTEPossibleindicationProphylaxisinpatientsathighriskforbothbleedingandVTEINFERIORVENACAVAFILTERSDefiINFERIORVENACAVAFILTERSThrombosisataccesssite(23-36%)MostasymptomaticLegswelling/ulceration(13-41%)Occlusionoffilter/IVCobstruction(4-11%)Recurrentpulmonaryembolism(2.6-3.8%)Tiltingoffilter(decreasedefficacy)(5%)Filtermigration(5%)MisplacementoffilterPerforationofvenacava,viscera,aortaMostfiltersdifficulttoremoveRemovablefiltersavailable,butsuccessfulremovalmoredifficultafter2-3moComplicationsanddisadvantagesINFERIORVENACAVAFILTERSThroPROPHYLACTICVENACAVAFILTERSPREVENTPEBUTDONOTREDUCEMORTALITY
RESULTSOFARANDOMIZEDCLINICALTRIALNEnglJMed1998;338:409GROUPPulmonaryEmbolismDeathMajorBleedingPulmonaryembolismRecurrentDVTDeathMajorBleedingFilter1.1%2.5%4.5%3.4%20.8%21.6%8.8%NoFilter4.8%2.5%3.0%6.3%11.6%20.1%11.8%Outcomeat12daysOutcomeat2yearsPROPHYLACTICVENACAVAFILTERSIVCFILTERSINCREASEVTERECURRENCERATEINCANCERPATIENTSArchInternMed.2004;164:1653-1661%WithoutRecurrenceIVCFILTERSINCREASEVTERECURVENACAVAFILTERSInpatientswithDVT,IVCfilters:ReducetheincidenceofpulmonaryembolismIncreasetheincidenceofrecurrentDVTDonotimprovesurvivalNocontrolledtrialstosupportroutineuseofIVCfiltersforthromboprophylaxisin“highrisk”patientswithoutDVTConclusionsVENACAVAFILTERSInpatientswTreatmentofacuteVTETreatmentofacuteVTEPrinciplesofVTETreatmentAdequatetreatmentofVTErequiresadministrationofarapid-actinganticoagulantThisdrugshouldbegivenindosessufficienttoachieveasystemicanticoagulanteffect,eg:UFH:70-80U/kgloadingdose,15-18U/kg/hinfusionwithaPTTmonitoringEnoxaparin:1mg/kgsqtwicedailyDalteparin:100U/kgsqtwicedailyFondaparinux:7.5mgsqdailyInitialtreatmentshouldbegivenforaminimumof5daysFailuretoadministersufficientdosesofarapid-actinganticoagulantmayincreaseriskofrecurrentVTEforuptothreemonthsNoroutinemonitoringPrinciplesofVTETreatmentAdeHeparinissuperiortoavitaminKantagonistforinitialtreatmentofacuteDVT12345678910111213141516171819202122Weeks02468101214CumulativefailuresHeparin+acenocoumarolAcenocoumarolaloneBrandjesetal,NEJM1992;327:1485HeparinissuperiortoavitamHEPARINSHOULDBEDOSEDACCORDINGTOBODYWEIGHTOutcomeStandarddoseWeight-baseddosePvalueFirstaPTT>1.5xcontrol,%3286<0.001aPTT>1.5xcontrolwithin24hours,%77970.002Minorbleeding,%3.83.2NSMajorbleeding,%1.90NSRecurrentDVT/PE,%2550.02Arandomized,controlledtrialin115patientswiththromboembolismorunstableangina(AnnInternMed1993;119:874)Weight-basedstartingdose:80U/kgbolus,18U/kg/hrStandardstartingdose:5000Ubolus,1000U/hrHEPARINSHOULDBEDOSEDACCORDHEPARIN"RESISTANCE"Inadequatedose(largepatient)Solution:weight-baseddosingaPTTprolongationlessthanusualdespitetherapeuticheparinlevel(baseaPTTshort)Solution:monitorheparinlevel(anti-Xaactivity)HeparinneutralizedbyPF4releasedduringclotformationSolution:LMWHLowplasmaantithrombinlevel(veryrarelyacause)Solution:antithrombinconcentrateorFFPinfusionHeparinantibodies(maycausethrombocytopeniaandthrombosis)Solution:alternativethrombininhibitor(lepirudin,etc);limitheparinexposurebystartingwarfarinearlyCausesandsolutionsHEPARIN"RESISTANCE"InadequateLOWMOLECULARWEIGHTHEPARINAdvantagesoverstandardheparinBetterbioavailabilityLongerhalf-lifeallowsonceortwicedailydosingFacilitatesoutpatienttreatmentMostpatientsdonotneedmonitoringLesslikelythantocauseHITLessbonemineralloss,lowerfractureriskDisadvantagesAccumulatesinrenalfailureNotwell-neutralizedbyprotamineLOWMOLECULARWEIGHTHEPARINAdENOXAPARINLEVELVSCREATININECLEARANCEJClinPharmacol2003;43:586-590Patientstreatedwithenoxaparin1mg/kgq12hConclusion:monitoringwarrantedwhenCrCl<30ENOXAPARINLEVELVSCREATININESTANDARDVSLMWHEPARINFOR
TREATMENTOFDVTmeta-analysisof10publishedtrialsArchInternMed1995;155:601-7Outcome%RiskreductionwithLMWH95%CISymptomaticthromboembolism5318-73Clinicallyimportantbleeding6831-85Mortality4710-69STANDARDVSLMWHEPARINFOR
TLMWHvsUFHLowmolecularweightheparinisatleastaseffectiveasunfractionatedheparininthetreatmentofacuteVTELowmolecularweightheparinhassignificantpracticaladvantagesoverunfractionatedheparinLMWHvsUFHLowmolecularweighINITIALTREATMENTOFVTE
ACCPrecommendationsInitialtreatment:LMWHonceortwicedailyUFHIVorsq(weight-baseddosingpreferred)Fondaparinux(7.5mg/day)LMWHpreferredforDVT(outpatient)ornon-massivePEUFHpreferredinpatientsreceivingthrombolyticdrugsorwhohavesevererenalfailureBeginwarfarinonday1EarlyambulationpreferredtobedrestContinueinitialtreatmentatleast5days,anduntilINR>2.0foratleast24hours2008ACCPguidelinesINITIALTREATMENTOFVTE
ACCPPreventionofrecurrentVTEPreventionofrecurrentVTEPREVENTIONOFRECURRENTVTEHulletal,JAMA1984;252:235TreatmentRecurrence(%)Bleeding(%)Warfarin(targetINR3-6)222Warfarin(targetINRabout1.8)24Lowdoseheparin(5000Usqbid)470Adjdoseheparin(PTTtarget1.5x)42ThreemonthfollowupPREVENTIONOFRECURRENTVTEHulWarfarinforpreventionofrecurrentVTELoadingdosenotnecessaryorbeneficialTakesminimumof4-5daystoestablishanticoagulanteffectINRdoesnotreflectanticoagulanteffectforfirst2-3daysTargetINR2-3WarfarinforpreventionofrecIttakesatleast4-5daysforwarfarintoachieveanadequateanticoagulanteffectClottingfactorlevelsafterstartingwarfarinIttakesatleast4-5daysforWHATISTHEOPTIMALINTENSITYOFWARFARINTREATMENTFORPREVENTIONOFRECURRENTVTE?AnINRbetween2and3isoptimalforsecondarypreventionofVTELessintenseanticoagulation(INR1.5-2)isbetterthanplacebo,butdoesnotsignificantlylowerbleedingriskandisassociatedwithahigherriskofrecurrentVTEConsiderforpatientswhostronglypreferlessfrequentmonitoring,asopposedtostoppingRxearlyThereareveryfew(ifany)situationsifanyinwhichanINR>3.0isnecessaryorbeneficial2008ACCPguidelinesWHATISTHEOPTIMALINTENSITYWARFARIN"FAILURE“
Causesandsolutions-1Inadequateinitialtreatment(increasesrecurrencerateforupto3months)AdequatedoseanddurationofinitialanticoagulantRx(UFHorLMWH)OverdiagnosisofrecurrentDVT(vspostphlebiticsyndrome)VenographyorMRvenographyifrecurrencesuspectedinareaofpriorDVTPoorcompliancePatienteducationPooranticoagulantcontrolCarefulmonitoringWARFARIN"FAILURE“
CausesandWARFARIN"FAILURE“
Causesandsolutions-2Underlyingmalignancy(warfarinlesseffective)EvaluateforoccultCALMWHifknownCAAntiphospholipidsyndrome(uncommon)ConsiderLMWHlong-termDelayedonsetHITwiththrombosis(rare;canoccuruptoamonthafterstoppingheparin)CheckforheparinantibodiesWARFARIN"FAILURE“
CausesandWarfarinvsLMWHforsecondarypreventionofVTEWarfarinvsLMWHforsecondaryLMWHISSUPERIORTOWARFARINFORPREVENTIONOFRECURRENTVTEINCANCERLeeetal,NEnglJMed2003;349:146-53LMWHISSUPERIORTOWARFARINFVTEeventsBleedingLMWHbetterOACbetterLMWHeparinvsoralanticoagulantsforpreventionofrecurrentVTE:ameta-analysisJThrombHaemost2003;1:1906VTEeventsBleedingLMWHbetterODurationofanticoagulationDurationofanticoagulationKaplan-Meierestimatesofcumulat
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年景区节假日节前旅游安全检查工作总结
- 2026年勘察设计注册土木工程师考试(水利水电工程专业知识)模拟题库及答案(云南省)
- 2026年度初级经济师考试民航运输经济训练题及答案
- 2026年初级经济师资格考试(工商管理专业知识和实务)冲刺模拟试题及答案
- 2025届恩施土家族苗族自治州鹤峰县四年级数学第二学期期中学业质量监测试题含答案解析
- 2025届广东省广州市花都区四年级数学第二学期期末联考模拟试题含答案解析
- 2026年初级新能源维修记录填写基础考试试卷及答案
- 2026年中药煎药卫生培训试题答案
- 2026年中小学心理健康教育工作实施方案
- 2026年初级新能源电池热失控风险基础识别考试试卷及答案
- 中医医院卒中中心脑出血救治流程
- 《股票价值评估用》课件
- 2027贵州航天电器秋季招聘284人考试备考题库及答案解析
- 地理信息数据分类分级工作指南试行全文
- 再生水回用处理工程设计
- 【新教材核心素养】教科版科学五年级上册3.3《用弹力驱动小车》教学课件
- 企业车间主任(班组长)岗位安全职责培训
- 氧、氮、氩气管道安装施工方案
- 小学五年级英语语法讲义
- 学校实习委托书范本
- 2026中铝物资面向中铝集团内部招聘9人备考题库及答案详解(全优)
评论
0/150
提交评论